Protein Therapeutics Market Overview :
Global Protein Therapeutics Market accounted for $140,109 million in 2016, and is anticipated to reach $217,591 million by 2023, registering a CAGR of 6.5% from 2017 to 2023. Therapeutic protein drugs are an important class of medicines, which are administered to treat an array of different diseases such as cancer, infectious diseases, and others. These drugs hold significant potential to improve human health.
The demand for protein therapeutics has increased considerably, owing to increase in prevalence of chronic diseases and development of plasma-derived therapies. Furthermore, surge in awareness with respect to protein therapeutics among populace boosts the market growth. However, high costs associated with therapeutic proteins and stringent government regulations towards protein therapeutics restrict market growth. Conversely, adoption of protein therapeutics for novel indications and untapped potential of developing countries are anticipated to provide lucrative opportunities to the market players.
The protein therapeutics market is segmented based product, application, and geography. Depending on product, the market is divided into monoclonal antibodies, insulin, fusion protein, erythropoietin, interferon, human growth hormone, and follicle stimulating hormone. The applications covered in this study include metabolic disorders, immunologic disorders, hematological disorders, cancer, hormonal disorders, genetic disorders, and others. Geographically, this market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Protein Therapeutics Market, By Geography, 2017-2023 ($Million)
North America generated the highest revenue in the protein therapeutics market in 2016. Asia-Pacific possesses high market potential, owing to increase in awareness about protein therapeutics-based treatments and rise in protein therapeutics applications.
Protein Therapeutics Market, By Product, 2017-2023 ($Million)
Monoclonal antibodies occupied the largest share in the global market, owing to the necessity and applicability of these products in the treatment of different chronic disorders.
Protein Therapeutics Market, By Application, 2017-2023 ($Million)
The report provides extensive competitive analysis and profiles of key market players, such as Abbott Laboratories, Amgen Inc., Baxter International Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co., Inc., Novo Nordisk A/S, Pfizer Inc., and Sanofi. Other players (profiles not included in the report) in the value chain analysis include Biogen, Inc., CSL Behring, and Genentech, Inc.
Key Benefits for Stakeholders
- The study provides an in-depth analysis of the global protein therapeutics market, with current trends and future estimations to elucidate the imminent investment pockets.
- A quantitative analysis from 2016 to 2023 to enable the stakeholders to capitalize on the prevailing market opportunities is discussed.
- Key market players are profiled and their strategies are analyzed thoroughly, which help understand the competitive outlook of the market.
- Porter’s Five Forces model interprets the bargaining power of suppliers & buyers, threat of new entrants & substitutes, and competition in the key players.
Protein Therapeutics Market Key Segments:
- Monoclonal Antibodies
- Fusion Protein
- Human Growth Hormone
- Follicle Stimulating Hormone
- Metabolic Disorders
- Immunologic Disorders
- Hematological Disorders
- Hormonal Disorders
- Genetic Disorders,
- North America
- Rest of Europe
- South Korea
- Rest of Asia-Pacific
- Saudi Arabia
- South Africa
- Rest of LAMEA